Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
暂无分享,去创建一个
Z. Jing | Kaifeng Xu | D. Kiely | V. Tapson | L. Rubin | E. Kotlyar | L. Pan | J. Feldman | C. Arneson | K. Laliberte | C. McSwain | Lewis J. Rubin